Case report of pulmonary embolism in pediatric practice

Cover Page

Cite item

Abstract

An analysis of the clinical situation of a 14-year-old patient with pulmonary embolism (PE) and current information on the risk factors for the development of thrombotic events are presented. Due to the presence of gynecological pathology, the girl was prescribed hormonal drugs, in particular, dydrogesterone and estrogen + gestagen. Against the background of its use, complaints of shortness of breath appeared, which was regarded as a manifestation of bronchial obstruction and bronchodilator therapy was prescribed. Due to the lack of positive dynamics during treatment, she was hospitalized. MSCT of the chest organs was performed: signs of PE were revealed; A molecular genetic study of the DNA of buccal epithelial cells (PCR) was carried out: the carriage of prothrombogenic polymorphic variants of genes of the hemostasis system was revealed, the most significant of which is a heterozygous mutation of the prothrombin FII gene (G20210A); the study of the hemostasis system revealed thrombinemia. In therapy, thrombolysis was not performed, low molecular weight heparins were prescribed – the child's condition improved. The question of the need for a comprehensive examination, including research on the carriage of prothrombogenic polymorphic variants of the genes of the hemostasis system for pediatric patients in situations requiring the administration of hormonal drugs for a long course, to prevent the ocurrence of dangerous thrombotic complications, is discussed.

Full Text

Restricted Access

About the authors

Tamara V. Belousova

Novosibirsk State Medical University

Email: belousovatv@ngs.ru
ORCID iD: 0000-0002-4234-9353

D. Sci. (Med.), Prof.

Russian Federation, Novosibirsk

Svetlana A. Loskutova

Novosibirsk State Medical University

Email: plyushkin@ngs.ru
ORCID iD: 0000-0003-2673-0880

D. Sci. (Med.)

Russian Federation, Novosibirsk

Anastasia O. Zatolokina

Novosibirsk State Medical University

Email: plyushkin@ngs.ru
ORCID iD: 0000-0002-6425-5024

assistant

Russian Federation, Novosibirsk

Valeriy A. Plyushkin

Novosibirsk State Medical University

Author for correspondence.
Email: plyushkin@ngs.ru
ORCID iD: 0000-0002-3402-839X

Cand. Sci. (Med.)

Russian Federation, Novosibirsk

References

  1. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(3):CD003177. doi: 10.1002/14651858.CD003177.pub5
  2. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1736-88. doi: 10.1016/S0140-6736(18)32203-7
  3. Строзенко Л.А. Первичная тромбопрофилактика у подростков на основе выявления и модификации постоянных и временных факторов тромбогенного риска: автореф. дис. ... д-ра мед. наук. М., 2014 [Strozenko LA. Pervichnaia tromboprofilaktika u podrostkov na osnove vyiavleniia i modifikatsii postoiannykh i vremennykh faktorov trombogennogo riska: avtoref. dis. ... d-ra med. nauk. Moscow, 2014 (in Russian)].
  4. Lassandro G, Palmieri VV, Palladino V, et al. Venous Thromboembolism in Children: From Diagnosis to Management. Int J Environ Res Public Health. 2020;17(14):4993. doi: 10.3390/ijerph17144993
  5. Баркаган З.С. Клинико-патогенетические варианты, номенклатура и основы диагностики гематогенных тромбофилий. Проблемы гематологии и переливания крови. 1996;3:5-15 [Barkagan ZS. Kliniko-patogeneticheskie varianty, nomenklatura i osnovy diagnostiki gematogennykh trombofilii. Problemy gematologii i perelivaniia krovi. 1996;3:5-15 (in Russian)].
  6. Момот А.П. Эволюция представлений о тромбофилии и ее роли в патологии человека. Геморрагические диатезы, тромбозы, тромбофилии. 2014;1:1-6 [Momot AP. Evoliutsiia predstavlenii o trombofilii i ee roli v patologii cheloveka. Gemorragicheskie diatezy, trombozy, trombofilii. 2014;1:1-6 (in Russian)].
  7. Момот А.П., Тараненко И.А., Цывкина Л.П. Состояние тромботической готовности – возможности современной диагностики и перспективы. Медицинский алфавит. Современная лаборатория. 2013;1:24-7 [Momot AP, Taranenko IA, Tsyvkina LP. Sostoianie tromboticheskoi gotovnosti – vozmozhnosti sovremennoi diagnostiki i perspektivy. Meditsinskii alfavit. Sovremennaia laboratoriia. 2013;1:24-7 (in Russian)].
  8. Abdelghani E, Cua CL, Giver J, Rodriguez V. Thrombosis prevention and anticoagulation management in the pediatric patient with congenital heart disease. Cardiol Ther. 2021;10(2):325-48. doi: 10.1007/s40119-021-00228-4
  9. Nowak-Göttl U, van Ommen H, Kenet G. Thrombophilia testing in children: what and when should be tested? Thromb Res. 2018;164:75-8. doi: 10.1016/j.thromres.2018.02.136
  10. Riedlova P, Kramna D, Ostrizkova S, et al. Examination of in Factor V Leiden and prothrombin II thrombophilic mutations in czech young women using ddPCR-prevalence and cost-benefit analysis. Healthcare (Basel). 2021;9(12):1656. doi: 10.3390/healthcare9121656
  11. Pумянцев А.Г., Масчан М.А., Жарков П.А., Свирин П.В. Федеральные клинические рекомендации по диагностике, профилактике и лечению тромбозов у детей и подростков. М., 2015 [Pumiantsev AG, Maschan MA, Zharkov PA, Svirin PV. Federal'nye klinicheskie rekomendatsii po diagnostike, profilaktike i lecheniiu trombozov u detei i podrostkov. Moscow, 2015 (in Russian)].
  12. Демехова М.Ю. Гормональная контрацепция и венозные тромбоэмболические осложнения у женщин. РМЖ. Мать и дитя. 2017;12:884-8 [Demekhova MYu. Hormonal contraception and venous thromboembolic complications in women. RMZh. Mat' i ditia. 2017;12:884-8 (in Russian)].
  13. De Bastos M, Stegeman BH, Rosendaal FR. Combined oral contraceptives: venous thrombosis (Review). Cochrane Database Syst Rev. 2014;3(3). DOI:CD010813
  14. Овчинников Ю.В., Панфилов Д.Н., Зеленов М.В., и др. Тромбоэмболия легочной артерии у женщин, принимающих пероральные гормональные контрацептивы. Клиническая медицина. 2015;93(10):58-66 [Ovchinnikov YuV, Panfilov DN, Zelenov MV, et al. Pulmonary thromboembolism in women using oral hormonal contraceptives. Klinicheskaia meditsina. 2015;93(10):58-66 (in Russian)].
  15. Chudej J, Plameňová I. Prothrombin gene 20210A mutation in Slovak population. Vnitr Lek. 2016;62(4):281-6.
  16. McLintock C. International Society on thrombosis and haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. J Thromb Haemost. 2016;14(1):3-27.
  17. Bergendal A, Persson I, Odeberg J. Association of Venous Thromboembolism With Hormonal Contraception and Thrombophilic Genotypes. Obstet Gynecol. 2014;124(3):600-9.
  18. Шелковникова Т.В., Тахчиди Х.П., Вавин Г.В., Шишлянникова Н.Ю. Венозные тромбоэмболические осложнения: случай из практики. РМЖ. Клиническая офтальмология. 2019;4:246-50 [Shelkovnikova TV, Takhchidi CP, Vavin GV, Shishlyannikova NYu. Venous Thromboembolic Events: Case History. RMZh. Klinicheskaia oftal'mologiia. 2019;4:246-50 (in Russian)]. doi: 10.32364/2311-7729-2019-19-4-246-250
  19. Животова Е.В., Лавыгина М.В., Галактионова М.Ю. Перспективы профилактической работы в условиях центров здоровья для детей. Сб. мат. XVII съезда педиатров России с международным участием «Актуальные проблемы педиатрии». М., 2013 [Zhivotova EV, Lavygina MV, Galaktionova MIu. Perspektivy profilakticheskoi raboty v usloviiakh tsentrov zdorov'ia dlia detei. Sb. mat. XVII s"ezda pediatrov Rossii s mezhdunarodnym uchastiem “Aktual'nye problemy pediatrii”. Moscow, 2013 (in Russian)].

Supplementary files

There are no supplementary files to display.


Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies